Sandbox endocarditis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 186: | Line 186: | ||
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Native Valve Endocarditis Caused by Highly Penicillin-Susceptible Viridans Group Streptococci and Streptococcus bovis}}'' | ! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Native Valve Endocarditis Caused by Highly Penicillin-Susceptible Viridans Group Streptococci and Streptococcus bovis}}'' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align=left | '''''Preferred Regimen''''' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[penicillin G sodium]] 12–18 million U/24 h IV either continuously or in 4 or 6 equally divided doses x 4 weeks'''''<BR>''OR''<BR> ▸ '''''[[Ceftriaxone|Ceftriaxone sodium]] 2 g/24 h IV/IM in 1 dose x 4 weeks''''' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[penicillin G sodium]] 12–18 million U/24 h IV either continuously or in 4 or 6 equally divided doses x 4 weeks'''''<BR>''OR''<BR> ▸ '''''[[Ceftriaxone|Ceftriaxone sodium]] 2 g/24 h IV/IM in 1 dose x 4 weeks''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 80%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[penicillin G sodium]] 200 000 U/kg q24h IV in 4–6 equally divided doses''''' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[penicillin G sodium]] 200 000 U/kg q24h IV in 4–6 equally divided doses''''' | ||
Line 196: | Line 196: | ||
|style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸'''''[[ceftriaxone]] 100 mg/kg q24 h IV/IM in 1 dose''''' | |style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸'''''[[ceftriaxone]] 100 mg/kg q24 h IV/IM in 1 dose''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align=left | '''''Alternative Regimen''''' | ||
|- | |- | ||
|style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''[[Penicillin G sodium]] 12–18 million U/24 h IV either continuously or in 6 equally divided doses x 2 weeks<BR>''OR''<BR> '''''[[Ceftriaxone|Ceftriaxone sodium]] 2 g/24 h IV/IM in 1 dose x 2weeks''''' | |style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''[[Penicillin G sodium]] 12–18 million U/24 h IV either continuously or in 6 equally divided doses x 2 weeks<BR>''OR''<BR> '''''[[Ceftriaxone|Ceftriaxone sodium]] 2 g/24 h IV/IM in 1 dose x 2weeks''''' | ||
Line 204: | Line 204: | ||
|style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |▸'''''[[Gentamicin|Gentamicin sulfate]] 3 mg/kg per 24 h IV/IM in 1 dose X 2 weeks''''' | |style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |▸'''''[[Gentamicin|Gentamicin sulfate]] 3 mg/kg per 24 h IV/IM in 1 dose X 2 weeks''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 80%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | ||
|- | |- | ||
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[penicillin G sodium]] 200 000 U/kg q24h IV in 4–6 equally divided doses''''' | | style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[penicillin G sodium]] 200 000 U/kg q24h IV in 4–6 equally divided doses''''' | ||
Line 211: | Line 211: | ||
|-style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸'''''[[Gentamicin]] 3 mg/kg per 24 h IV/IM in 1 dose or 3 equally divided doses''' | |-style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸'''''[[Gentamicin]] 3 mg/kg per 24 h IV/IM in 1 dose or 3 equally divided doses''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 100%; background: #F5F5F5" align=left | '''''Alternative Regimen''''' | ||
|- | |- | ||
|style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''[[Vancomycin|Vancomycin hydrochloride]] 15 mg/kg q12h IV x 4 weeks,doses not to exceed 2 g/24 h unless concentrations in serum are inappropriately low''''' | |style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''[[Vancomycin|Vancomycin hydrochloride]] 15 mg/kg q12h IV x 4 weeks,doses not to exceed 2 g/24 h unless concentrations in serum are inappropriately low''''' | ||
|- | |- | ||
! style="padding: 0 5px; font-size: | ! style="padding: 0 5px; font-size: 80%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pediatric dose}}'' | ||
|- | |- | ||
|style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |▸'''''[[Vancomycin|Vancomycin hydrochloride]] 40 mg/kg per 24 h IV in 2–3 equally divided doses''''' | |style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |▸'''''[[Vancomycin|Vancomycin hydrochloride]] 40 mg/kg per 24 h IV in 2–3 equally divided doses''''' | ||
|- | |- | ||
|} | |} | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} |
Revision as of 16:21, 15 January 2014
Empirical Antibiotic Therapy
- Antibiotic therapy for subacute disease, and in those who have received antibiotics recently can be delayed waiting the results of blood cultures, as this delay allows an additional blood cultures without the confounding effect of empiric treatment, which is very important in determining the causing pathogens.[1]
- On the other hand, the rapid progression of acute cases necessitate the start of empirical treatment antibiotic therapy once the blood cultures have been collected.
- Empirical therapy is needed for all likely pathogens, certain antibiotic agents, including aminoglycosides, is preferably avoided for its toxic effects.
- Clinical course of infection beside the epidemiological features should be considered upon selecting empirical treatment regimen.
- Consultation with an infectious disease specialist for the selection of one of the antibiotic regimens is recommended(See therapy for culture-negative endocarditis). [2]
|